ATE457025T1 - Kinaseinhibitoren - Google Patents
KinaseinhibitorenInfo
- Publication number
- ATE457025T1 ATE457025T1 AT03722065T AT03722065T ATE457025T1 AT E457025 T1 ATE457025 T1 AT E457025T1 AT 03722065 T AT03722065 T AT 03722065T AT 03722065 T AT03722065 T AT 03722065T AT E457025 T1 ATE457025 T1 AT E457025T1
- Authority
- AT
- Austria
- Prior art keywords
- kinase inhibitors
- compound
- formula
- diastereomers
- solvates
- Prior art date
Links
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 102000001253 Protein Kinase Human genes 0.000 abstract 1
- 239000013078 crystal Chemical group 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 150000004677 hydrates Chemical group 0.000 abstract 1
- 108060006633 protein kinase Proteins 0.000 abstract 1
- 150000003839 salts Chemical group 0.000 abstract 1
- 239000012453 solvate Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Biotechnology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pain & Pain Management (AREA)
- AIDS & HIV (AREA)
- Dermatology (AREA)
- Neurology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AUPS2514A AUPS251402A0 (en) | 2002-05-23 | 2002-05-23 | Kinase inhibitors |
| US39899802P | 2002-07-26 | 2002-07-26 | |
| PCT/AU2003/000628 WO2003099811A1 (en) | 2002-05-23 | 2003-05-23 | Kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE457025T1 true ATE457025T1 (de) | 2010-02-15 |
Family
ID=29585025
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03722065T ATE457025T1 (de) | 2002-05-23 | 2003-05-23 | Kinaseinhibitoren |
Country Status (11)
| Country | Link |
|---|---|
| US (4) | US7259179B2 (de) |
| EP (1) | EP1511742B1 (de) |
| CN (1) | CN1671696B (de) |
| AT (1) | ATE457025T1 (de) |
| AU (1) | AU2003229370B2 (de) |
| CA (1) | CA2486187C (de) |
| DE (1) | DE60331187D1 (de) |
| GB (1) | GB2398781B (de) |
| IL (2) | IL165262A0 (de) |
| NZ (1) | NZ537156A (de) |
| WO (1) | WO2003099811A1 (de) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA06002018A (es) * | 2003-08-21 | 2006-05-31 | Osi Pharm Inc | Bencimidazolilo n-sustituidos inhibidores de c-kit. |
| AU2004278382B2 (en) * | 2003-09-30 | 2008-09-18 | Amgen Inc. | Vanilloid receptor ligands and their use in treatments |
| AU2004294355B2 (en) * | 2003-12-03 | 2011-12-22 | Ym Biosciences Australia Pty Ltd | Azole-based kinase inhibitors |
| CA2545425C (en) | 2003-12-03 | 2013-09-24 | Cytopia Research Pty Ltd | Azole-based kinase inhibitors |
| AU2005203919B2 (en) * | 2004-01-12 | 2011-07-21 | Ym Biosciences Australia Pty Ltd | Selective kinase inhibitors |
| DK1704145T3 (da) * | 2004-01-12 | 2012-09-24 | Ym Biosciences Australia Pty | Selektive kinaseinhibitorer |
| DK1750713T3 (da) | 2004-06-04 | 2013-02-11 | Bioniche Life Sciences Inc | Anvendelse af imatinib til behandling af leversygdomme og vi-rusinfektioner |
| KR20070086865A (ko) * | 2004-12-01 | 2007-08-27 | 오에스아이 파마슈티컬스, 인코포레이티드 | Ｎ-치환된 벤즈이미다졸일 ｃ-ｋｉｔ 억제제 및 조합적인벤즈이미다졸 라이브러리 |
| KR20080013886A (ko) * | 2005-04-05 | 2008-02-13 | 파마코페이아, 인코포레이티드 | 면역억제용 퓨린 및 이미다조피리딘 유도체 |
| NZ566021A (en) * | 2005-07-26 | 2011-03-31 | Vertex Pharma | Benzimidazoles useful as inhibitors of protein kinases |
| EP1988776B1 (de) * | 2006-03-02 | 2012-08-08 | Siga Technologies, Inc. | Antivirale mittel zur behandlung von arenavirus-infektionen |
| US8871746B2 (en) | 2006-03-02 | 2014-10-28 | Kineta Four, LLC | Antiviral drugs for treatment of arenavirus infection |
| US7977365B2 (en) | 2006-03-02 | 2011-07-12 | Siga Technologies, Inc. | Antiviral drugs for treatment of arenavirus infection |
| EP2001476A4 (de) | 2006-03-20 | 2010-12-22 | Synta Pharmaceuticals Corp | Benzoimidazolyl-parazin-verbindungen zur verwendung gegen entzündungs- und immunspezifische erkrankungen |
| US8604031B2 (en) * | 2006-05-18 | 2013-12-10 | Mannkind Corporation | Intracellular kinase inhibitors |
| EP2099774A4 (de) | 2006-11-15 | 2010-11-24 | Ym Biosciences Australia Pty L | Inhibitoren von kinaseaktivität |
| US8131527B1 (en) | 2006-12-22 | 2012-03-06 | Astex Therapeutics Ltd. | FGFR pharmacophore compounds |
| MX2009006704A (es) * | 2006-12-22 | 2009-06-30 | Astex Therapeutics Ltd | Derivados de amina triciclicos como inhibidores de proteina de tirosina cinasa. |
| TWI415609B (zh) * | 2006-12-22 | 2013-11-21 | Astex Therapeutics Ltd | 新化合物 |
| MX2009006706A (es) | 2006-12-22 | 2009-07-02 | Astex Therapeutics Ltd | Compuestos heterociclicos biciclicos como inhibidores del receptor del factor de crecimiento de fibroblastos. |
| US8415358B2 (en) | 2007-09-17 | 2013-04-09 | Neurosearch A/S | Pyrazine derivatives and their use as potassium channel modulators |
| GB0720041D0 (en) | 2007-10-12 | 2007-11-21 | Astex Therapeutics Ltd | New Compounds |
| GB0720038D0 (en) * | 2007-10-12 | 2007-11-21 | Astex Therapeutics Ltd | New compounds |
| US8008013B2 (en) * | 2007-11-16 | 2011-08-30 | Oklahoma Medical Research Foundation | Predicting and diagnosing patients with autoimmune disease |
| WO2009119776A1 (ja) * | 2008-03-27 | 2009-10-01 | 武田薬品工業株式会社 | 縮合複素環誘導体およびその用途 |
| MX2010012080A (es) * | 2008-05-05 | 2011-04-11 | Univ Winthrop Hospital | Metodo para mejorar el perfil de riesgo cardiovascular de los inhibidores de cox. |
| GB0810902D0 (en) | 2008-06-13 | 2008-07-23 | Astex Therapeutics Ltd | New compounds |
| WO2010012745A2 (en) * | 2008-07-29 | 2010-02-04 | Boehringer Ingelheim International Gmbh | Benzimidazoles |
| GB0906470D0 (en) | 2009-04-15 | 2009-05-20 | Astex Therapeutics Ltd | New compounds |
| GB0906472D0 (en) | 2009-04-15 | 2009-05-20 | Astex Therapeutics Ltd | New compounds |
| CA2797694A1 (en) * | 2010-04-29 | 2011-11-03 | The United States Of America, As Represented By The Secretary, Departmen T Of Health And Human Services | Activators of human pyruvate kinase |
| JP5868996B2 (ja) | 2010-12-13 | 2016-02-24 | アレイ バイオファーマ、インコーポレイテッド | ＩＩＩ型受容体チロシンキナーゼ阻害剤としての置換Ｎ−（１Ｈ−インダゾール−４−イル）イミダゾ［１，２−ａ］ピリジン−３−カルボキサミド化合物 |
| WO2012112567A1 (en) * | 2011-02-15 | 2012-08-23 | Georgetown University | Small molecule inhibitors of agbl2 |
| ES2917222T3 (es) | 2011-12-28 | 2022-07-07 | Kyoto Prefectural Public Univ Corp | Normalización del cultivo de células endoteliales de la córnea |
| EA035349B1 (ru) | 2012-11-21 | 2020-05-29 | ПиТиСи ТЕРАПЬЮТИКС, ИНК. | ЗАМЕЩЕННЫЕ ПИРИМИДИНОВЫЕ ОБРАТНЫЕ ИНГИБИТОРЫ Bmi-1 |
| EP3007689B1 (de) | 2013-01-10 | 2018-03-07 | Pulmokine, Inc. | Nicht-selektive kinasehemmer |
| HK1220325A1 (zh) | 2013-03-15 | 2017-05-05 | Whitehead Institute For Biomedical Research | 苯并咪唑衍生物及其用途 |
| EP3054937B1 (de) | 2013-10-11 | 2023-07-26 | Pulmokine, Inc. | Sprühtrocknungsformulierungen |
| JP6730701B2 (ja) | 2013-11-14 | 2020-07-29 | 学校法人同志社 | 細胞増殖促進または細胞障害抑制による角膜内皮治療薬 |
| WO2015076800A1 (en) | 2013-11-21 | 2015-05-28 | Ptc Therapeutics, Inc. | Substituted pyridine and pyrazine bmi-1 inhibitors |
| WO2018013430A2 (en) | 2016-07-12 | 2018-01-18 | Arisan Therapeutics Inc. | Heterocyclic compounds for the treatment of arenavirus infection |
| KR20230093341A (ko) | 2016-10-27 | 2023-06-27 | 풀모킨 인코포레이티드 | 폐고혈압을 치료하기 위한 병용 요법 |
| AU2019340402B2 (en) | 2018-08-17 | 2025-04-03 | Ptc Therapeutics, Inc. | Method for treating pancreatic cancer |
| US12419865B2 (en) | 2018-12-06 | 2025-09-23 | Arisan Therapeutics Inc. | Compounds for the treatment of arenavirus infection |
| WO2023220046A1 (en) * | 2022-05-10 | 2023-11-16 | Biogen Ma Inc. | Tyk2 inhibitors |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7125875B2 (en) | 1999-04-15 | 2006-10-24 | Bristol-Myers Squibb Company | Cyclic protein tyrosine kinase inhibitors |
| PT1169038E (pt) * | 1999-04-15 | 2012-10-26 | Bristol Myers Squibb Co | Inibidores cíclicos da proteína tirosina cinase |
| JP2004528295A (ja) | 2001-01-30 | 2004-09-16 | サイトピア ピーティワイ リミテッド | キナーゼ阻害方法 |
| GB0215775D0 (en) * | 2002-07-06 | 2002-08-14 | Astex Technology Ltd | Pharmaceutical compounds |
-
2003
- 2003-05-23 WO PCT/AU2003/000628 patent/WO2003099811A1/en not_active Ceased
- 2003-05-23 IL IL16526203A patent/IL165262A0/xx active IP Right Grant
- 2003-05-23 CN CN038174529A patent/CN1671696B/zh not_active Expired - Fee Related
- 2003-05-23 EP EP03722065A patent/EP1511742B1/de not_active Expired - Lifetime
- 2003-05-23 AT AT03722065T patent/ATE457025T1/de not_active IP Right Cessation
- 2003-05-23 GB GB0318343A patent/GB2398781B/en not_active Expired - Lifetime
- 2003-05-23 DE DE60331187T patent/DE60331187D1/de not_active Expired - Lifetime
- 2003-05-23 CA CA2486187A patent/CA2486187C/en not_active Expired - Fee Related
- 2003-05-23 NZ NZ537156A patent/NZ537156A/en not_active IP Right Cessation
- 2003-05-23 AU AU2003229370A patent/AU2003229370B2/en not_active Ceased
- 2003-05-23 US US10/472,156 patent/US7259179B2/en not_active Expired - Lifetime
-
2004
- 2004-11-16 IL IL165262A patent/IL165262A/en unknown
-
2006
- 2006-04-04 US US11/397,973 patent/US7598272B2/en not_active Expired - Lifetime
- 2006-04-04 US US11/397,982 patent/US7511047B2/en not_active Expired - Lifetime
-
2007
- 2007-02-27 US US11/711,957 patent/US20070161635A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN1671696B (zh) | 2010-12-08 |
| US20070161635A1 (en) | 2007-07-12 |
| AU2003229370A1 (en) | 2003-12-12 |
| AU2003229370B2 (en) | 2009-02-26 |
| US20050004140A1 (en) | 2005-01-06 |
| CN1671696A (zh) | 2005-09-21 |
| DE60331187D1 (de) | 2010-03-25 |
| US7511047B2 (en) | 2009-03-31 |
| EP1511742B1 (de) | 2010-02-03 |
| GB0318343D0 (en) | 2003-09-10 |
| US20060241112A1 (en) | 2006-10-26 |
| NZ537156A (en) | 2007-06-29 |
| EP1511742A4 (de) | 2006-07-05 |
| WO2003099811A1 (en) | 2003-12-04 |
| US20060270687A1 (en) | 2006-11-30 |
| CA2486187C (en) | 2013-02-19 |
| GB2398781B (en) | 2005-02-02 |
| EP1511742A1 (de) | 2005-03-09 |
| CA2486187A1 (en) | 2003-12-04 |
| IL165262A0 (en) | 2005-12-18 |
| GB2398781A (en) | 2004-09-01 |
| US7598272B2 (en) | 2009-10-06 |
| US7259179B2 (en) | 2007-08-21 |
| IL165262A (en) | 2011-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60317198D1 (de) | Proteinkinaseinhibitoren | |
| ATE457025T1 (de) | Kinaseinhibitoren | |
| SG128491A1 (en) | Heterocyclic sulfonamide inhibitors of beta amyloid production | |
| BG108181A (bg) | Нови спиротрициклични производни и тяхното използване като инхибитори на фосфодиестераза-7 | |
| NO20051600L (no) | 1,4-disubstituerte piperidinderivater og anvendelse derav som 11-betaHSD1 inhibitorer | |
| EA200501009A1 (ru) | Замещённые пирролопиразольные производные в качестве ингибиторов киназы | |
| NO20054195D0 (no) | Isoksazolforbindelser som inhibitorer for varmesjokkproteiner | |
| NO20005237D0 (no) | Heterocyklisk substituerte amider anvendt som calpain- inhibitorer | |
| BRPI0407841A (pt) | inibidores heterocìclicos de quinase | |
| EA200301276A1 (ru) | Новые производные сульфоновых кислот | |
| ECSP055809A (es) | Inhibidores 4-oxo-1-(3-fenil sustituido)-1,4-dihidro-1,8-naftiridina-3-carboxamida de la fosfodiesterasa-4 | |
| ATE303384T1 (de) | 1-biaryl-1,8-naphthyridin-4-one als phosphodieseterase-inhibitoren | |
| TNSN06138A1 (fr) | Inhibitors of the mutant form of kit | |
| DE602004005881D1 (de) | Substituierte pyrazinonverbindungen zur behandlung von entzündungen | |
| ATE333457T1 (de) | Zyklische gmp-spezifische phosphodiesteraseinhibitoren | |
| EA200600898A1 (ru) | Новый способ синтеза периндоприла и его фармацевтически приемлемых солей | |
| EA200501900A1 (ru) | Новый способ синтеза периндоприла и его фармацевтически приемлемых солей | |
| EA200301101A1 (ru) | Производные пиперазина и их применение в качестве ингибиторов pde4 | |
| NO20030297L (no) | Aryl sulfonamider som serotoninantagonist for behandling av fedme | |
| EA200600456A1 (ru) | Новый способ синтеза периндоприла и его фармацевтически приемлемых солей | |
| EA200600455A1 (ru) | Новый способ синтеза периндоприла и его фармацевтически приемлемых солей | |
| NO20061302L (no) | Derivater av hydroksaminsyre som metalloproteinseinbitorer | |
| EA200600454A1 (ru) | Новый способ синтеза периндоприла и его фармацевтически приемлемых солей | |
| EA200601086A1 (ru) | Новый способ синтеза периндоприла и его фармацевтически приемлемых солей | |
| EA200600250A1 (ru) | Новый способ синтеза периндоприла и его фармацевтически приемлемых солей |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |